# Use antibodies to deliver protein-destroying drugs into the right cells

Source: https://onco.cc/ideas/idea-bio1-antibody-degrader-conjugates/  
OnCo record `idea-bio1-antibody-degrader-conjugates` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Drugs that destroy proteins can hit healthy cells too. Attaching them to an antibody that only docks onto tumour cells would keep them where they are needed.

## Summary

Degrader-antibody conjugates replace cytotoxic payloads with a targeted protein degrader, so the payload is only released inside antigen-positive cells. Early programmes target BRD4 and other essential proteins that are too toxic to degrade systemically. This is a route to attack undruggable but essential nuclear proteins that would otherwise be intolerable.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: A degrader-antibody conjugate produces antigen-dependent degradation of an essential nuclear target in vivo with a therapeutic window at least five-fold wider than the free degrader.
- Rationale: ADC linker and payload technology is mature; the constraint on degrading essential proteins is normal-tissue exposure, exactly the problem conjugation solves. Bystander effects may also address antigen heterogeneity.
- Proposed test: Compare matched free degrader and conjugate in an antigen-positive versus antigen-negative xenograft pair, with tumour and normal-tissue degradation pharmacodynamics and marrow toxicity as endpoints.
- Maturity: preclinical-evidence
- Actor: industry

## Sources

- Bottleneck evidence (The undruggable drivers): Dang et al., Drugging the 'undruggable' cancer targets (Nature Reviews Cancer 2017): https://doi.org/10.1038/nrc.2017.36

## Connected records

- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Degrader-antibody conjugate (DAC)](https://onco.cc/technologies/degrader-antibody-conjugate/), [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/)
- companies: [Kymera Therapeutics](https://onco.cc/companies/kymera/), [Nurix Therapeutics](https://onco.cc/companies/nurix/), [Sutro Biopharma](https://onco.cc/companies/sutro-biopharma/)
- terms: [Bystander effect (ADC)](https://onco.cc/terms/bystander-effect/), [Payload (ADC)](https://onco.cc/terms/payload/)
- bottlenecks: [The undruggable drivers](https://onco.cc/bottlenecks/b-undruggable-targets/), [Toxicity and quality of life are undervalued](https://onco.cc/bottlenecks/b-toxicity-qol/)
- key papers: [Drugging the 'undruggable' cancer targets](https://onco.cc/key-papers/paper-dang-nat-rev-cancer/)

---
JSON: https://onco.cc/api/v1/entities/idea-bio1-antibody-degrader-conjugates.json